Quarterly ResultAug 6, 2026, 02:38 PM
Zoetis Q2 Diluted EPS $1.65; Revenue $2.47B; Restructuring Charges Up
AI Summary
Zoetis reported mixed financial results for the second quarter of 2026, with diluted earnings per share increasing to $1.65, while revenue slightly decreased to $2.468 billion and net income fell to $691 million. The company incurred significantly higher restructuring charges of $77 million, primarily due to employee termination costs. Zoetis also announced an agreement to acquire Neogen’s animal genomics business, expected to close in the second half of 2026.
Key Highlights
- Diluted EPS for Q2 2026 increased to $1.65 from $1.63 year-over-year.
- Total revenue for Q2 2026 was $2.468 billion, a slight decrease from $2.474 billion YoY.
- Net income attributable to Zoetis Inc. for Q2 2026 decreased to $691 million from $726 million YoY.
- Restructuring charges and acquisition-related costs rose to $77 million in Q2 2026 from $30 million YoY.
- Net cash used in financing activities was $1,653 million for the six months ended June 30, 2026.
- International revenue for Q2 2026 increased to $1,173 million from $1,085 million YoY.
- Zoetis agreed to acquire Neogen’s animal genomics business, expected to close in H2 2026.
- Dividends declared per common share increased to $0.530 in Q2 2026 from $0.500 YoY.
Price Impact
More from ZTS